Stemline Therapeutics Inc (STML) Receives Consensus Recommendation of “Buy” from Analysts

Stemline Therapeutics Inc (NASDAQ:STML) has been assigned an average rating of “Buy” from the eight analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $33.75.

A number of research firms recently weighed in on STML. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. BidaskClub raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 14th. Finally, Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st.

Stemline Therapeutics (STML) opened at $13.55 on Friday. The firm has a market capitalization of $340.11, a P/E ratio of -5.27 and a beta of -0.02. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $16.20.

Stemline Therapeutics (NASDAQ:STML) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.11). Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. equities research analysts anticipate that Stemline Therapeutics will post -2.71 EPS for the current year.

In related news, COO Kenneth Hoberman sold 11,943 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $14.18, for a total value of $169,351.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Gionco sold 4,250 shares of the business’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $13.43, for a total value of $57,077.50. The disclosure for this sale can be found here. Insiders have sold a total of 42,216 shares of company stock worth $591,925 over the last three months. 16.70% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Stemline Therapeutics by 4.7% in the 2nd quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock valued at $7,946,000 after purchasing an additional 38,615 shares during the period. Lyon Street Capital LLC boosted its stake in Stemline Therapeutics by 331.1% in the 3rd quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock valued at $6,010,000 after purchasing an additional 415,867 shares during the period. State Street Corp boosted its stake in Stemline Therapeutics by 11.3% in the 2nd quarter. State Street Corp now owns 345,363 shares of the biopharmaceutical company’s stock valued at $3,179,000 after purchasing an additional 35,116 shares during the period. Northern Trust Corp boosted its stake in Stemline Therapeutics by 18.0% in the 2nd quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock valued at $2,529,000 after purchasing an additional 41,898 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Stemline Therapeutics by 82.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 219,252 shares of the biopharmaceutical company’s stock valued at $2,434,000 after purchasing an additional 98,775 shares during the period. Institutional investors and hedge funds own 50.24% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Stemline Therapeutics Inc (STML) Receives Consensus Recommendation of “Buy” from Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/20/stemline-therapeutics-inc-stml-receives-consensus-recommendation-of-buy-from-analysts.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply